当前位置: X-MOL 学术J. Rheumatol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Development of Pulmonary Alveolar Proteinosis in a Patient With Adult-Onset Still Disease Treated With Tocilizumab.
The Journal of Rheumatology ( IF 3.6 ) Pub Date : 2022-08-15 , DOI: 10.3899/jrheum.220128
Yuhei Ito 1 , Hiroki Nakahara 2 , Ayako Nakajima 3
Affiliation  

We report a patient with systemic adult-onset Still disease (AOSD) who developed anti-granulocyte-macrophage colony-stimulating factor (GM-CSF)-positive pulmonary alveolar proteinosis (PAP) while using tocilizumab (TCZ), diagnosed by milky white bronchoalveolar lavage fluid (BALF; Figure 1). To our knowledge, this is the first case of PAP in AOSD.

中文翻译:

使用 Tocilizumab 治疗的成年发病 Still 疾病患者肺泡蛋白沉积症的发展。

我们报告了一名患有全身性成人发作 Still 病 (AOSD) 的患者,该患者在使用托珠单抗 (TCZ) 时出现了抗粒细胞-巨噬细胞集落刺激因子 (GM-CSF) 阳性肺泡蛋白沉积症 (PAP),诊断为乳白色支气管肺泡灌洗液(BALF;图 1)。据我们所知,这是 AOSD 中的第一例 PAP。
更新日期:2022-08-15
down
wechat
bug